IE49126B1 - An isoxazole derivative,processes for its preparation,compositions containing it,and its use for combating rheumatism - Google Patents

An isoxazole derivative,processes for its preparation,compositions containing it,and its use for combating rheumatism

Info

Publication number
IE49126B1
IE49126B1 IE2426/79A IE242679A IE49126B1 IE 49126 B1 IE49126 B1 IE 49126B1 IE 2426/79 A IE2426/79 A IE 2426/79A IE 242679 A IE242679 A IE 242679A IE 49126 B1 IE49126 B1 IE 49126B1
Authority
IE
Ireland
Prior art keywords
formula
acid
compound
trifluoromethyl
methylisoxazole
Prior art date
Application number
IE2426/79A
Other languages
English (en)
Other versions
IE792426L (en
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of IE792426L publication Critical patent/IE792426L/xx
Publication of IE49126B1 publication Critical patent/IE49126B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Lubricants (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IE2426/79A 1978-12-16 1979-12-14 An isoxazole derivative,processes for its preparation,compositions containing it,and its use for combating rheumatism IE49126B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19782854439 DE2854439A1 (de) 1978-12-16 1978-12-16 Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung

Publications (2)

Publication Number Publication Date
IE792426L IE792426L (en) 1980-06-16
IE49126B1 true IE49126B1 (en) 1985-08-07

Family

ID=6057414

Family Applications (1)

Application Number Title Priority Date Filing Date
IE2426/79A IE49126B1 (en) 1978-12-16 1979-12-14 An isoxazole derivative,processes for its preparation,compositions containing it,and its use for combating rheumatism

Country Status (25)

Country Link
US (2) US4284786A (OSRAM)
EP (1) EP0013376B1 (OSRAM)
JP (1) JPS5583767A (OSRAM)
AR (2) AR222680A1 (OSRAM)
AT (1) ATE1067T1 (OSRAM)
AU (1) AU529341B2 (OSRAM)
BG (1) BG60764B2 (OSRAM)
CA (1) CA1129867A (OSRAM)
DE (2) DE2854439A1 (OSRAM)
DK (1) DK149886C (OSRAM)
EG (1) EG13926A (OSRAM)
ES (2) ES486750A1 (OSRAM)
FI (1) FI64154C (OSRAM)
GR (1) GR72731B (OSRAM)
HU (1) HU178015B (OSRAM)
IE (1) IE49126B1 (OSRAM)
IL (1) IL58951A (OSRAM)
LU (1) LU90466I2 (OSRAM)
MX (2) MX6174E (OSRAM)
NL (1) NL990037I2 (OSRAM)
NO (1) NO148925C (OSRAM)
NZ (1) NZ192400A (OSRAM)
PH (1) PH16627A (OSRAM)
PT (1) PT70596A (OSRAM)
ZA (1) ZA796793B (OSRAM)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3247454A1 (de) * 1982-12-22 1984-06-28 Laboratorios Bago S.A., Buenos Aires Substituierte 3-phenyl-5-methyl-isoxazol-4-carboxy-anilide, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
FR2538806B1 (fr) * 1982-12-30 1986-02-21 Bago Sa Labor Composes phenyl-3 methyl isoxazole-5 carboxy-4 anilides substitues, actifs therapeutiquement contre l'inflammation et la douleur
US5268382A (en) * 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
US4935434A (en) * 1988-01-26 1990-06-19 Bristol-Myers Company Antiarthritic isoxazole-4-carboxamides
FR2662692B1 (fr) * 1990-05-30 1995-04-28 Novapharme Derives heterocycliques doues d'activite anticonvulsivante, procede de preparation et composition pharmaceutique.
US5258397A (en) * 1988-11-30 1993-11-02 Novapharme 3-Isoxazoyl derivatives endowed with anticonvulsant activity, procedure for their preparation and their pharmaceutical compositions
DD297328A5 (de) * 1989-08-18 1992-01-09 �������@���������k���Kk�� 5-methyl-isoxalol-4-carbonsaeureanilide und 2 hydroxyethyliden-cyanoessigsaeureanilide zur behandlung von augenerkrankungen
US5583150A (en) * 1989-08-18 1996-12-10 Alcon Laboratories, Inc. 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
US5108999A (en) * 1990-02-02 1992-04-28 Syntex (U.S.A.) Inc. 4-isoxazolecarboxamide derivatives
US5001124A (en) * 1990-02-02 1991-03-19 Syntex (U.S.A.) Inc. 4-isoxazolecarboxamide derivatives
KR100188801B1 (ko) * 1990-05-18 1999-06-01 엥겔하르트 라피체 이속사졸-4카복스아미드 및 하이드록시알킬리덴 시아노아세트아미드 및 이들 화합물을 함유하는 약제학적 조성물
DE4127737A1 (de) * 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
US6133301A (en) * 1991-08-22 2000-10-17 Aventis Pharma Deutschland Gmbh Pharmaceuticals for the treatment of rejection reactions in organ transplantations
ES2124800T3 (es) * 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion de interleuquina 1 beta.
ES2124801T3 (es) * 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion del factor de necrosis de tumores alfa.
ATE174220T1 (de) * 1993-01-08 1998-12-15 Hoechst Ag Verwendung von leflunomid zur hemmung von interleukin 8
EP0607774B1 (de) * 1993-01-08 1998-12-09 Hoechst Aktiengesellschaft Verwendung von Leflunomid zur Hemmung von Interleukin 1 alpha
TW314467B (OSRAM) * 1993-03-31 1997-09-01 Hoechst Ag
DE4323636A1 (de) * 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
LT3589B (en) 1993-11-30 1995-12-27 Hoechst Ag Using of known combination for treatment of rejection reaction by transplantation of organs
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US6335356B1 (en) 1994-01-07 2002-01-01 Sugen, Inc. Method of treating a patient by parenteral administration of a lipophilic compound
US5519042A (en) * 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease
US5624946A (en) * 1994-07-05 1997-04-29 Williams; James Use of leflunomide to control and reverse chronic allograft rejection
US5814649A (en) * 1994-10-17 1998-09-29 Hoechst Pharmaceuticals & Chemicals K.K. Preventive and remedy for type 1 allergic diseases
US5721277A (en) * 1995-04-21 1998-02-24 Sugen, Inc. Compounds and methods for inhibiting hyper-proliferative cell growth
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
DE19539638A1 (de) * 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
DE19702988A1 (de) * 1997-01-28 1998-07-30 Hoechst Ag Isoxazol- und Crotonsäureamidderivate und deren Verwendung als Arzneimittel und Diagnostika
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
PT987256E (pt) * 1997-08-08 2002-03-28 Aventis Pharma Gmbh Forma cristalina da n-(4-trifluorometilfenil)-5-metil-isoxazol-4-carboxamida
US7691890B2 (en) 1998-03-11 2010-04-06 James W. Williams Anti-viral uses of leflunomide products
US20050255071A1 (en) * 1998-12-10 2005-11-17 Aventis Pharma Deutschland Gmbh Preparation having improved therapeutic breadth comprising nucleotide synthesis inhibitors
DE19908527C2 (de) 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
US6566395B1 (en) 1999-05-25 2003-05-20 Biomedicines, Inc. Methods of treating proliferative disorders
DE19960443C2 (de) * 1999-12-15 2002-05-08 Aventis Pharma Gmbh Verfahren zur Auffindung von Nukleotidsyntheseinhibitoren mit weniger Nebenwirkungen
CZ20022000A3 (cs) * 1999-12-16 2003-02-12 Teva Pharmaceuticals Industries Ltd. Způsoby přípravy a nová krystalická forma leflunomidu
EP1473035A1 (en) * 2000-02-15 2004-11-03 Teva Pharmaceutical Industries Ltd. Leflunomide of high purity
JP2004500380A (ja) 2000-02-15 2004-01-08 テバ　ファーマシューティカル　インダストリーズ　リミティド レフルノミドの合成方法
AU2001284891A1 (en) * 2000-08-14 2002-02-25 Teva Pharmaceutical Industries Ltd. Micronized leflunomide
PT1381356E (pt) 2001-04-05 2008-07-24 Aventis Pharma Inc Utilização de (4' -trifluorometilfenil) - amida do ácido (z) -2- ciano-3-hidroxi-but-2-enóico para tratamento da esclerose múltipla
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US20030139606A1 (en) * 2001-11-09 2003-07-24 Ray Anup Kumar Process for preparing 5-methylisoxazole-4-carboxylic- (4'-trifluoromethyl)-anilide
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
US20060024376A1 (en) * 2004-07-30 2006-02-02 The University Of Chicago Methods and compositions for reducing toxicity associated with leflunomide treatment
JPWO2007026737A1 (ja) * 2005-08-31 2009-03-12 興和株式会社 関節リウマチの予防及び／又は治療法
EP2125895B1 (en) 2007-02-02 2015-04-08 Vegenics Pty Ltd Vegf receptor antagonists for treating organ transplant alloimmunity and arteriosclerosis
CN101817797B (zh) * 2009-02-26 2013-04-10 江苏亚邦爱普森药业有限公司 高纯度3-甲基-n-[4-(三氟甲基)苯基]-4-异噁唑甲酰胺的合成方法
US9138309B2 (en) 2010-02-05 2015-09-22 Allergan, Inc. Porous materials, methods of making and uses
US9205577B2 (en) * 2010-02-05 2015-12-08 Allergan, Inc. Porogen compositions, methods of making and uses
US11202853B2 (en) * 2010-05-11 2021-12-21 Allergan, Inc. Porogen compositions, methods of making and uses
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
JP2021519334A (ja) 2018-03-26 2021-08-10 クリア クリーク バイオ， インコーポレイテッド ジヒドロオロト酸デヒドロゲナーゼを阻害するための組成物および方法
CA3145269A1 (en) 2019-07-22 2021-01-28 Michel BURCKLEN Use of ponesimod for the treatment of multiple sclerosis
AU2021232637A1 (en) 2020-03-06 2022-09-22 Actelion Pharmaceuticals Ltd Methods of slowing brain volume loss
US20210300873A1 (en) 2020-03-20 2021-09-30 Clear Creek Bio, Inc. Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof
WO2023062511A1 (en) 2021-10-11 2023-04-20 Actelion Pharmaceuticals Ltd Methods of treating multiple sclerosis
WO2023061935A1 (en) 2021-10-11 2023-04-20 Actelion Pharmaceuticals Ltd Methods of treating multiple sclerosis
CA3220702A1 (en) 2022-02-11 2023-08-17 Actelion Pharmaceuticals Ltd Methods of slowing an increase in brain ventricular volume

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087534A (en) * 1974-05-22 1978-05-02 David Ovadia N-haloalkylmio urazole pesticides
DE2524959C2 (de) * 1975-06-05 1983-02-10 Hoechst Ag, 6000 Frankfurt 5-Methyl-isoxazol-4-carbonsäureanilide, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Mittel
ES448386A1 (es) * 1975-06-05 1978-04-16 Hoechst Ag Procedimiento para la preparacion de anilidas de acido 5-me-til-isoxazol-4-carboxilico.
DE2654797A1 (de) * 1976-12-03 1978-06-08 Hoechst Ag Verfahren zur herstellung von isoxazolderivaten

Also Published As

Publication number Publication date
NO148925B (no) 1983-10-03
DK149886C (da) 1987-04-21
EP0013376B1 (de) 1982-05-19
AU5385379A (en) 1980-06-19
EP0013376A2 (de) 1980-07-23
MX6174E (es) 1984-12-04
GR72731B (OSRAM) 1983-12-01
ES486758A1 (es) 1980-05-16
ES486750A1 (es) 1980-06-16
JPH0133470B2 (OSRAM) 1989-07-13
IE792426L (en) 1980-06-16
FI64154C (fi) 1983-10-10
PH16627A (en) 1983-12-05
JPS5583767A (en) 1980-06-24
AR226894A1 (es) 1982-08-31
NL990037I1 (nl) 2000-01-03
NO148925C (no) 1984-01-11
MX8403A (es) 1994-03-31
LU90466I2 (fr) 2000-01-03
ZA796793B (en) 1980-11-26
EP0013376A3 (en) 1980-09-17
CA1129867A (en) 1982-08-17
ATE1067T1 (de) 1982-06-15
BG60764B2 (bg) 1996-02-29
FI64154B (fi) 1983-06-30
AU529341B2 (en) 1983-06-02
US4284786A (en) 1981-08-18
DK149886B (da) 1986-10-20
FI793899A7 (fi) 1980-06-17
IL58951A0 (en) 1980-03-31
EG13926A (en) 1982-09-30
NO794094L (no) 1980-06-17
PT70596A (de) 1980-01-01
US4351841A (en) 1982-09-28
DK534279A (da) 1980-06-17
HU178015B (en) 1982-02-28
IL58951A (en) 1984-01-31
DE2854439A1 (de) 1980-07-03
NL990037I2 (nl) 2000-01-03
DE2962929D1 (en) 1982-07-08
NZ192400A (en) 1982-02-23
AR222680A1 (es) 1981-06-15

Similar Documents

Publication Publication Date Title
IE49126B1 (en) An isoxazole derivative,processes for its preparation,compositions containing it,and its use for combating rheumatism
US4476137A (en) [1-(2-Benzoxazolyl)hydrazino]alkyl nitrile derivatives
JPS62161728A (ja) 抗菌剤
CS267551B1 (en) Pharmaceutical agents for asthma treatment and method of effective substance production
JPH0667919B2 (ja) 新規なインデノチアゾ−ル誘導体及びその製造法
US4294851A (en) Aminobenzoic acid derivatives
US4636513A (en) Isoxazole derivatives and medicaments containing these compounds
SU1199197A3 (ru) Способ получени производных фенилалкановой кислоты
US3402198A (en) 2-(phenoxy), 2-(phenylthio) and 2-(anilino) substituted 2-alkylideneacetic acid derivatives
JPH0692915A (ja) １，２−ジアミノシクロブテン−３，４−ジオン誘導体及びその用途
US4473583A (en) Compositions containing certain derivatives of 4-phenyl-4-oxobuten-2-oic acid and methods of treatment using them
US4490376A (en) Substituted ethenyl derivatives of 1H-pyrazolo-[1,5-a]pyrimidine having gastroenteric activity, compositions thereof, and methods of using the same
CS216206B2 (en) Method of making the derivatives of the diphenylpyrazole
CA1132983A (fr) Procedes de preparation de nouvelles piperazines monosubstituees
US4867737A (en) Derivatives of 4-phenyl-4-oxo-2-butenoic acid their preparation process, their use as medicaments and compositions containing them
JPH0227325B2 (OSRAM)
US3133933A (en) Certain
IE43706B1 (en) Substituted haloacetophenone oximes
US4333938A (en) Imino derivatives of 5-aminobenzodioxole-1,3 which are useful as medicaments
JPS63126860A (ja) グアニジノメチル安息香酸誘導体
HU184965B (en) Process for producing phenyl-piperazine derivatives of anti-agression activity
JPS5951542B2 (ja) ５−フエニル−チアゾリジン−４−オン誘導体の製造方法
US4228166A (en) 2-Keto-4,5-dihydro-3 (2H)-pyridazinones, and their use in treating muscle tension
KR810000473B1 (ko) N-2,6-디클로로페닐-2-아미노피리미딘의 제법
BE882071A (fr) Composes du guanidinothiazole utiles comme inhibiteurs des secretions d'acide gastrique, leurs procedes de preparation et les compositions medicales contenant de tels composes

Legal Events

Date Code Title Description
SPCF Request for grant of supplementary protection certificate

Free format text: SPC 17/99, 19991020

MK9A Patent expired
SPCG Supplementary protection certificate granted

Free format text: SPC017/99, 20000522, EXPIRES: 20041213